Graham C Johnson

US Patent:

20200055840, Feb 20, 2020

Filed:

Oct 25, 2019

Appl. No.:

16/664621

Inventors:

- Boston MA, US
- Oakland CA, US
Rudolph E. Tanzi - Hull MA, US
Graham Johnson - Sanbornton NH, US
Ronald Buckle - Delmar NY, US
Nicholas Mayhew - Niskayuna NY, US
Robert Jason Herr - Voorheesville NY, US
Kevin D. Rynearson - La Mesa CA, US

International Classification:

C07D 401/14
A61P 25/28
C07D 487/04
C07D 413/14

Abstract:

Provided herein are compounds and methods for treating a disorder associated with aberrant Aβ peptide levels, including Alzheimer's disease.

US Patent:

20180093967, Apr 5, 2018

Filed:

Oct 30, 2015

Appl. No.:

15/522969

Inventors:

- Boston MA, US
- Oakland CA, US
Rudolph E. Tanzi - Hull MA, US
Graham Johnson - Sanbornton NH, US
Ronald Buckle - Delmar NY, US
Nicholas Mayhew - Niskayuna NY, US
Robert Jason Herr - Voorheesville NY, US
Kevin D. Rynearson - La Mesa CA, US

International Classification:

C07D 401/14
C07D 413/14
C07D 487/04
A61P 25/28

Abstract:

Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.